These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26980523)

  • 1. Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.
    Hondeghem LM
    Prog Biophys Mol Biol; 2016 May; 121(1):3-10. PubMed ID: 26980523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
    Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
    J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C; Sterneberg M; Kochhäuser S; Dechering DG; Fehr M; Eckardt L; Frommeyer G
    Europace; 2018 Oct; 20(10):1699-1706. PubMed ID: 29377987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM; Carlsson L; Duker G
    Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM
    Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM
    Novartis Found Symp; 2005; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oscillations of cardiac wave length and proarrhythmia.
    Hondeghem LM; Dumotier B; Traebert M
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Oct; 382(4):367-76. PubMed ID: 20803191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart.
    Asano Y; Davidenko JM; Baxter WT; Gray RA; Jalife J
    J Am Coll Cardiol; 1997 Mar; 29(4):831-42. PubMed ID: 9091531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem LM
    Drug Saf; 2018 Jan; 41(1):11-17. PubMed ID: 28853038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.